Dr. Reddy's Laboratories Announce Launch of Desmopressin Acetate Injection

The following is from a press release from Dr. Reddy’s Laboratories. Read the press release in its entirety here.

Dr. Reddy’s Laboratories Ltd., along with its subsidiaries together referred to as “Dr. Reddy’s” today announced the launch of Desmopressin Acetate Injection USP, 4 mcg/mL Single-dose Ampules, a therapeutic equivalent generic version of DDAVP (desmopressin acetate) Injection , 4 mcg/mL, approved by the U.S. Food and Drug Administration.
The DDAVP (desmopressin acetate) Injection USP brand and generic market had U.S. sales of approximately $20.9 million MAT for the most recent twelve months ending in March 2020 according to IQVIA Health*.
Marc Kikuchi, CEO, North America Generics, Dr. Reddy’s Laboratories, commented, “The launch of Desmopressin Injection demonstrates a strong, growing collaboration with SunGen Pharma. We look forward to future opportunities with this company.”
 
Read the press release in its entirety here.